Hussman Strategic Advisors Inc. Purchases Shares of 42,000 Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Hussman Strategic Advisors purchased a new stake of 42,000 shares of Immunocore, worth about $1.46 million, representing roughly 0.08% of the company at quarter-end.
• Institutional investors now own 84.50% of IMCR with notable stake increases from firms like Marshall Wace, RBC and Geode, while insiders have sold about 19,137 shares over the last 90 days (insiders own 10.4% of the company).
• Immunocore remains loss-making (latest quarterly EPS -$0.60) with a market cap near $1.43 billion, mixed analyst ratings and a consensus price target of $60.89.

Hussman Strategic Advisors Inc. purchased a new stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 42,000 shares of the company's stock, valued at approximately $1,458,000. Hussman Strategic Advisors Inc. owned approximately 0.08% of Immunocore at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of IMCR. Royal Bank of Canada increased its stake in Immunocore by 45.1% during the 1st quarter. Royal Bank of Canada now owns 44,011 shares of the company's stock valued at $1,306,000 after purchasing an additional 13,689 shares in the last quarter. Geode Capital Management LLC increased its stake in Immunocore by 40.1% during the 2nd quarter. Geode Capital Management LLC now owns 52,001 shares of the company's stock valued at $1,632,000 after purchasing an additional 14,877 shares in the last quarter. Marshall Wace LLP increased its stake in Immunocore by 425.8% during the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company's stock valued at $4,601,000 after purchasing an additional 118,728 shares in the last quarter. Sei Investments Co. acquired a new position in Immunocore during the 2nd quarter valued at approximately $983,000. Finally, Cubist Systematic Strategies LLC increased its stake in Immunocore by 108.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 142,757 shares of the company's stock valued at $4,480,000 after purchasing an additional 74,128 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Stock Performance

IMCR opened at $28.16 on Monday. The company has a quick ratio of 4.01, a current ratio of 4.04 and a debt-to-equity ratio of 1.03. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -40.23 and a beta of 0.74. Immunocore Holdings PLC Sponsored ADR has a 52-week low of $27.44 and a 52-week high of $40.71. The firm's fifty day simple moving average is $31.05 and its two-hundred day simple moving average is $33.40.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. The company had revenue of $104.48 million for the quarter. Immunocore had a negative net margin of 8.88% and a negative return on equity of 9.20%. Equities analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on IMCR. Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. Mizuho set a $38.00 price target on shares of Immunocore in a research note on Thursday, February 19th. Zacks Research lowered shares of Immunocore from a "hold" rating to a "strong sell" rating in a research note on Monday, April 27th. UBS Group set a $55.00 target price on shares of Immunocore and gave the stock a "buy" rating in a report on Wednesday, January 7th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Immunocore in a report on Tuesday, April 21st. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $60.89.

Insider Buying and Selling at Immunocore

In other Immunocore news, insider David M. Berman sold 5,965 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the transaction, the insider directly owned 5,859 shares of the company's stock, valued at $189,538.65. This trade represents a 50.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bahija Jallal sold 11,474 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $371,183.90. Following the transaction, the chief executive officer directly owned 12,343 shares in the company, valued at approximately $399,296.05. The trade was a 48.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 19,137 shares of company stock valued at $619,082 over the last ninety days. Corporate insiders own 10.40% of the company's stock.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body's own T‐cell response to treat cancer and infectious diseases. The company's proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company's most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.

Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.